A2Z Cust2Mate Solutions Corp (AZ) Stock News

Jazz Pharmaceuticals is expected to report a year-over-year earnings decline with higher revenues when it releases Q3 2026 results on November 2. With an Earnings ESP of 0% and Zacks Rank #3, the stock is not considered a compelling earnings-beat candidate. The company has beaten consensus estimates in 3 of the last 4 quarters but missed the most recent quarter by 5.46%.

AutoZone stock declined 2.14% on October 23, 2026, underperforming the S&P 500's 0.52% loss. Despite a strong 14.29% monthly gain, the stock faces headwinds with a 1.49% decrease in consensus EPS estimates over the past 30 days. The company holds a Zacks Rank #3 (Hold) with a Forward P/E of 19.07, trading at a premium to its industry average. Upcoming earnings are expected to show 17.3% year-over-year EPS growth to $36.41 per share.

Astrazeneca (AZN) closed at $166.68, up 2.87% in the latest session, outperforming the S&P 500. The pharmaceutical company is trading at a Forward P/E of 17.28, below its industry average of 25.3, suggesting a valuation discount. However, the stock holds a Zacks Rank #3 (Hold) rating with projected Q3 EPS declining 9.24% year-over-year, though full-year earnings are expected to grow 2.4%. The Medical - Biomedical and Genetics industry ranks in the bottom 38% of all industries.

AZZ (electrical equipment maker) closed down 1.54% and underperformed the S&P 500. The company is expected to report earnings on October 13, 2026, with forecasted EPS of $1.82 (up 17.42% YoY) and revenue of $461.79 million (up 10.67% YoY). AZZ holds a Zacks Rank #3 (Hold) with a Forward P/E of 19.63, trading at a discount to its industry average of 24.38.

Astrazeneca (AZN) closed at $158.61, up 1.33%, outperforming the S&P 500. The pharmaceutical company is expected to report earnings on October 30, 2026, with predicted EPS of $2.16 (down 9.24% YoY) and revenue of $16.07 billion (up 5.82% YoY). AZN holds a Zacks Rank #3 (Hold) with a Forward P/E of 16.71, trading at a discount to its industry average of 22.46.

Astrazeneca stock fell 1.17% on September 29, 2026, underperforming the S&P 500's 0.17% decline. The pharmaceutical company is expected to report earnings on October 30, 2026, with predicted EPS of $2.17 (down 8.82% YoY) and revenue of $16.07 billion (up 5.82% YoY). AZN holds a Zacks Rank #3 (Hold) with a Forward P/E of 17.73, trading at a discount to its industry average of 25.2.

AutoZone reported Q3 2026 earnings of $56.05 per share, beating consensus estimates of $54.54 by 2.77%, but revenues of $6.59 billion missed expectations by 1.38%. The stock has underperformed the S&P 500 by 30.8 percentage points year-to-date. AutoZone received a Zacks Rank #3 (Hold) rating with mixed estimate revisions, suggesting near-term performance in line with the market.

AstraZeneca closed at $168.10, up 1.22% but lagging the S&P 500's 1.49% gain. The stock has risen only 0.06% over the past month while underperforming its sector. Upcoming earnings are expected to show EPS of $2.17 (down 8.82% YoY) with revenue of $16.07 billion (up 5.82% YoY). The company received a Zacks Rank of #5 (Strong Sell) following an 8.49% decline in consensus EPS estimates over the past month.

AstraZeneca and Merck are compared as investment opportunities in the pharmaceutical sector. AstraZeneca targets $80 billion in revenues by 2030 with 20 planned new medicine launches but faces patent expirations, pricing pressures in China, and recent pipeline setbacks. Merck relies heavily on blockbuster drug Keytruda (peak sales $35 billion by 2028) but faces patent expiration in 2028 and biosimilar competition. Merck receives a Zacks Rank #3 (Hold) while AstraZeneca receives Zacks Rank #5 (Strong Sell), making Merck the preferred choice despite higher valuation multiples.

AutoZone is expected to report Q4 earnings of $54.97 per share, representing a 12.9% year-over-year increase, with revenues projected at $6.71 billion, up 7.5% from the prior year quarter. Analysts forecast domestic commercial sales of $1.95 billion (+10.6% YoY) and same-store sales growth of 3.7%, though this represents a slowdown from the prior year's 4.8%. The company is projected to expand its store count to 8,017 locations globally. However, AutoZone carries a Zacks Rank #4 (Sell) rating and has underperformed the market, declining 7.4% over the past month compared to the S&P 500's -2.9% decline.

Netanyahu steps up threats against directors of Gaza documentary 'NAZA'  Reuters

While Wall Street analysts maintain a bullish average brokerage recommendation (ABR) of 1.56 for Astrazeneca with 17 Strong Buy ratings, the Zacks Rank system assigns the stock a Strong Sell rating (#5). This contradiction stems from a 10.3% decline in consensus earnings estimates over the past month to $9.16, indicating analyst pessimism about the company's earnings prospects. The article cautions investors against relying solely on brokerage recommendations, which often exhibit positive bias, and suggests the Zacks Rank's focus on earnings estimate revisions is a more reliable predictor of near-term stock performance.

Astrazeneca (AZN) rose 2.25% to $163.78 in the latest session, outperforming the broader market decline. However, the company faces headwinds with consensus EPS estimates down 8.49% over the last 30 days and a Zacks Rank of #4 (Sell). While revenue is expected to grow 5.82% year-over-year, the stock trades at a forward P/E of 17.14, below its industry average, and the Medical-Biomedical and Genetics industry ranks in the bottom 34% of all sectors.

AZZ closed at $132.75, down 3.15%, underperforming the S&P 500's 0.48% loss. The stock has declined 9.44% over the past month, lagging its Industrial Products sector. However, earnings projections show growth with EPS expected at $1.8 (up 16.13% YoY) and revenue at $458.04 million (up 9.77% YoY). AZZ holds a Zacks Rank #3 (Hold) with a Forward P/E of 19.78, trading at a discount to its industry average.

AstraZeneca announced that its phase III SERENA-4 study evaluating Etcamah combined with Pfizer's Ibrance failed to meet its primary endpoint of progression-free survival as first-line treatment for ER-positive, HER2-negative advanced breast cancer, though numerical improvement was observed. The failure does not affect Etcamah's recent FDA approval for a switch strategy in patients with ESR1 resistance mutations.

AstraZeneca's stock has fallen 19.5% in six months due to several clinical and pipeline setbacks, including failed studies for Wainua and Ultomiris, and FDA delays for camizestrant. However, the company maintains solid fundamentals with 16 blockbuster drugs, 15% oncology sales growth, and targets $80 billion in revenues by 2030 with 20 new medicines planned. Despite headwinds from patent expirations and China market uncertainties, analysts recommend staying invested given growth prospects.

AstraZeneca announced positive Phase III SANOVO study results showing that Tagrisso (osimertinib) combined with Orpathys (savolitinib) significantly improved progression-free survival versus Tagrisso monotherapy in treatment-naïve patients with EGFR-mutated advanced NSCLC with MET overexpression. The combination also demonstrated encouraging overall survival improvements. These results could expand the clinical utility of the combination to first-line treatment settings.

Pomerantz LLP is investigating potential securities fraud at Azenta, Inc. following the resignation of CEO John Marotta on August 24, 2026. The announcement triggered a significant stock price decline of 12.09% ($4.52 per share), closing at $32.88. Investors are being invited to join a class action lawsuit.

Jazz Pharmaceuticals announced second interim results from the HERIZON-GEA-01 study showing statistically significant overall survival improvements for Ziihera plus chemotherapy versus standard of care trastuzumab plus chemotherapy in HER2-positive gastroesophageal adenocarcinoma. The three-drug regimen of Ziihera plus Tevimbra and chemotherapy also demonstrated improved OS hazard ratios with longer follow-up. These results support the recent FDA label expansion of Ziihera for first-line treatment in this indication, significantly expanding its commercial opportunity.

The article compares brokerage recommendations (ABR) with Zacks Rank as investment tools. While AZZ has a favorable average brokerage recommendation of 1.80 (Strong Buy equivalent), the article cautions that brokerage analysts are often overly optimistic due to vested interests. Zacks Rank, which is based on earnings estimate revisions, is presented as a more reliable predictor of stock price movements. AZZ received a Zacks Rank #3 (Hold) rating due to unchanged earnings estimates, suggesting caution despite the positive brokerage sentiment.

The regional sports networks that air games for local New York and New Jersey teams, including MLB's Yankees and NHL's Rangers, will have a new streaming home.

Pomerantz LLP announced investigations into potential securities fraud at AstraZeneca following the failure of its Phase-3 CARDIO-Transform trial for Wainua treatment, which caused the stock to drop 5.7%. The firm is also investigating claims against Alibaba Group and Franklin Covey Co.

Dimensional Fund Advisors Ltd. has disclosed a 0.89% stake in Beazley PLC, comprising 5,332,927 ordinary shares as of June 30, 2026. The disclosure includes a sale of 730,460 shares at 12.8662 GBP per unit and a transfer in of 497 shares. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 80,720 of the shares included in the total.

Dimensional Fund Advisors Ltd. has disclosed a 1.06% interest in Beazley PLC comprising 6,353,668 ordinary shares as of June 26, 2026. The disclosure was made under Rule 8.3 of the Takeover Code. Recent dealings included sales of shares at prices around 12.85 GBP per unit.

Dimensional Fund Advisors Ltd. has disclosed a 1.16% interest in Beazley PLC, comprising 6,950,983 ordinary shares as of June 25, 2026. The disclosure includes recent dealings involving sales of shares at prices around 12.84-12.85 GBP and a transfer out of 503,000 shares. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 112,090 of the disclosed shares.

Rocket Lab successfully launched the VICTUS HAZE mission for the U.S. Space Force in 16 hours and 42 minutes after receiving the launch notice, breaking the previous responsive space record by over 10 hours. The company delivered a complete end-to-end solution including spacecraft design, build, launch, and on-orbit operations, with the Pioneer spacecraft now conducting complex rendezvous and proximity operations in low Earth orbit.

Dimensional Fund Advisors Ltd. has disclosed a 1.67% interest in Beazley PLC, comprising 10,019,549 ordinary shares as of June 15, 2026. The disclosure includes a sale of 98,459 shares at 12.83 GBP per unit and a transfer in of 4,826 shares. Dimensional expressly disclaims beneficial ownership and notes it lacks discretion over 162,517 of the shares disclosed.

K-Tech Solutions Company Limited and Aurora AZ Energy Ltd. announced that construction has begun on an initial 5 MW capacity phase of their joint venture to develop computing infrastructure in Alberta, Canada. The project includes onsite technical testing to validate the integration of Aurora's natural gas power infrastructure with K-Tech's high-density computing systems, serving as a proof-of-concept for a planned 100 MW flagship deployment.

Harrow announced the re-launch of VERKAZIA, a prescription therapy for vernal keratoconjunctivitis (VKC), a chronic allergic eye disease primarily affecting children. The company is implementing a comprehensive commercial strategy focused on physician education, patient access, and affordability. VERKAZIA is a calcineurin inhibitor that addresses underlying inflammatory mechanisms and reduces the need for steroid rescue therapy, which carries risks like glaucoma and cataract formation.

Daz 3D announced the release of Daz Studio 6, featuring Victoria AI Chat integrated directly into the application, faster asset loading, improved content organization, and support for the latest NVIDIA GPUs. The update focuses on reducing workflow interruptions for 3D artists through enhanced tools for managing large content libraries, viewport performance improvements, and new rendering capabilities.